If this is your company, CONTACT US to activate Packbase™ software to build your portal.

    Webpackaging logo

    Pulmonary and Nasal Drug Delivery Experts to attend RDD Europe 2017

    Quick Contact
    • Aptar Pharma
    Pulmonary and Nasal Drug Delivery Experts to attend RDD Europe 2017
    Europe, France, Switzerland, France, Italy, Health, Pharmaceuticals, Medical, Diagnostics, Hospitals, Premium, Primary Packaging, Aerosols, Drug Delivery Devices, Laboratory, Testing, Certification, Shows, Associations, Media, Packaging Awards

    The Respiratory Drug Delivery (RDD®) Europe 2017 scientific conference will welcome pulmonary and nasal drug delivery experts from around the world to Antibes, France, April 25-28, 2017. The joint organizers of this event, RDD Online® and Aptar Pharma invite you to register.

    Bringing the Respiratory World Together

    Respiratory Drug Delivery Europe is a major conference bringing together experts from around the world to exchange emerging scientific knowledge and providing a dynamic forum for business networking. Approximately 450 delegates from 29 countries attended the 2015 edition in Antibes, France.

    RDD Europe attracts high level academic, industrial and regulatory scientists and clinicians. It is a must attend conference for companies involved in the research, development, testing and marketing of medicines, devices and services associated with pulmonary or nasal products.

    A premium, interactive three-day conference

    This year, the conference will start with a plenary lecture entitled “Patient Focused Device Design: Addressing Inhaler Technique”, hosted by Federico Lavorini, M.D. PhD, Department of Experimental and Respiratory Medicine, Careggi University Hospital, Florence, Italy.

    Subsequent sessions will focus on:

    • Progress in Inhaled Drug Development
    • Can Connected Devices Improve Respiratory Outcomes?
    • Changing Regulations in Europe - Achieving Deposition Equivalence
    • Novel Approaches to Characterize Aerosol Dynamics
    • Designing Inhalation Products in a Quality by Design Era

    As part of the conference, RDD Europe 2017 will underline innovative research contributions in both podium and scientific poster sessions. Scientific posters will highlight recent nasal and pulmonary pharmaceutical research. Five of the best posters will be showcased during ‘Posters on the Podium,’ a fast-paced interactive session in the main auditorium. All accepted graduate student poster abstracts are automatically eligible for the VCU RDD Peter R. Byron Graduate Student Award.

    RDD Europe 2017 will also host 12 workshops led by device experts and service providers. Participants can self-select and attend interactive technical Workshops highlighting innovative technologies, products and services.

    Valuable networking opportunities

    RDD Europe 2017 offers numerous networking opportunities including the Technology Exhibition. Exhibitors display innovative technologies and services throughout the conference in our signature table-top format. Device and equipment designers, and service providers, and consultants can interact and share their input.

    A networking cocktail reception will take place on the evening of April 25 and a Gala Dinner sponsored by Aptar Pharma will be hosted on Thursday, April 27.

    For many years, RDD Europe events have reached capacity, so early registration is strongly recommended. The early bird rate will be available until January 16, 2017.

    See also

    New FDA approved combination product with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that its VP3 multidose device is the delivery system for Glenmark’s Ryaltris™ nasal spray, which recently received New Drug Application (NDA) approval by the U.S. Food and Drug Administration. New FDA approved combination product for seasonal allergic rhinitis symptoms with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma granted exclusive license option by Pharmaxis to develop and promote high payload dry powder inhaler

    Aptar Pharma have entered into an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ proprietary high payload dry powder inhaler, Orbital. As part of the agreement, Aptar Pharma will evaluate the commercial applications for the Orbital device and further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbital intellectual property used to deliver inhaled mannitol.

    Noble and Aptar Pharma launch AdhereIT, a connected medical device solution for disease management adherence and onboarding patients

    Noble and Aptar Pharma are pleased to announce the launch of AdhereIT - a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home. AdhereIT is the first fully interchangeable, connected add-on solution that can work across a multitude of autoinjector platforms.

    Aptar Seeks FDA Emergency Use Authorization for Decontaminating N95 Masks with ActivShield

    AptarGroup, Inc. is seeking U.S. FDA Emergency Use Authorization (EUA) for a solution that allows easy disinfecting of N95 filtering facepiece respirators (N95 masks) using their ActivShieldTM. The N95 masks are desperately needed by healthcare personnel due to the shortage of disposable masks during the COVID-19 pandemic and this simple disinfecting process lets medical professionals reuse the masks after decontaminition.

    Aptar Pharma’s Nasal Unidose Device approved by US FDA for new nasal seizure rescue treatment

    Aptar Pharma has announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the U.S. FDA as a rescue treatment for people with epilepsy aged six and older suffering from acute repetitive seizures. Aptar’s Unidose Liquid System is a single-use, ready-to-use one-step nasal delivery device which can deliver a formulation in an emergency situation quickly and easily.

    Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation

    Aptar Pharma has announced that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the delivery system for Allergan’s REFRESH RELIEVA PF, its new over-the-counter (OTC) preservative-free treatment for eye dryness in the U.S. This use reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the multidose delivery system for ophthalmic agents and formulations without preservatives.

    Aptar’s Nasal Unidose Device approved by US FDA

    AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

    Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

    AptarGroup, Inc. has announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

    Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award

    Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.

    • Company News
    • English
    • Modified 10 Jan 2017
    • Hits 1280
    SR Packaging
    Webpackaging
    Conzept International